Chitosan-based delivery systems for mucosal vaccines

Expert Opinion on Drug Delivery

Volumn 9, Issue 9, 2012, Pages 1051-1067

  Jabbal Gill, Inderjit ^a   Watts, Peter ^a   Smith, Alan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Chitosan; Chitosan derivatives; Mucosal; Nanoparticles; Nasal,; Oral; Vaccine

Indexed keywords

ANTHRAX TOXIN; CHITOSAN; CHITOSAN DERIVATIVE; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HYALURONIC ACID; INFLUENZA VACCINE; NANOPARTICLE; PERTUSSIS TOXIN; PIPERAZINE DERIVATIVE; RECOMBINANT ANTIGEN; SUBUNIT VACCINE; TETANUS TOXOID; VACCINE;

AQUEOUS SOLUTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MEMBRANE MICROPARTICLE; MUCOADHESION; MUCOSAL IMMUNITY; NONHUMAN; PUBLISHING; REVIEW; SURFACE CHARGE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; BIOCOMPATIBLE MATERIALS; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; MOUTH MUCOSA; NANOPARTICLES; NASAL MUCOSA; VACCINATION; VACCINES;

EID: 84865319308     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.697455     Document Type: Review

References (104)

1. Neutra MR, Kozlowski PA. 2006;Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6(2):148-58
2. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7(4):265-76.Review (Pubitemid 17146794)
3. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target 2010;18(10):771-86
4. Modlin JF. Poliomyelitis in the United States: the final chapter? JAMA 2004;292(14):1749-51 (Pubitemid 39346680)
5. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011;239(1):125-48
6. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174(Suppl 1):S65-72 (Pubitemid 26293124)
7. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294(21):2720-5 (Pubitemid 41770101)
8. Times of India. First indigenous nasal vaccine for H1N1 is here. Available from: http://pune.aarogya.com/index. php/news-and-update/first- indigenous-nasal-vaccine-for-h1n1-is-here [Accessed 26 March 2012]
9. Garg NK, Mangal S, Khambete H, Tyagi RK. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010;4(2):114-28
10. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010;62(1):59-82
11. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996;86(3):345-8; Review (Pubitemid 26272074)
12. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp Med 2004;200(6):749-59 (Pubitemid 39299461)
13. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007;45(Suppl 1):S15-19 (Pubitemid 47036019)
14. Roberts GAF. Chitin chemistry. The Macmillan Press Ltd; London: 1992
15. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules 2008;9(7):1837-42
16. Mourya VK, Inamdar NN. Trimethyl chitosan and its applications in drug delivery. Mater Sci Mater Med 2009;20(5):1057-79
17. Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Marine Biotechnol 2006;8(3):203-26
18. Sashiwa H, Kawasaki N, Nakayama A, et al. Chemical modification of chitosan. Part 15: synthesis of novel chitosan derivatives by substitution of hydrophilic amine using N-carboxyethylchitosan ethyl ester as an intermediate. Carbohydr Res 2003;338(6):557-61 (Pubitemid 36351257)
19. Bernkop-Schnurch A, Guggi D, Pinter Y. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release 2004;94(1):177-86 (Pubitemid 37542387)
20. Roldo M, Hornof M, Caliceti P, Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm 2004;57(1):115-21 (Pubitemid 38058810)
21. Holme KR, Perlin AS. Chitosan N-sulfate. A water-soluble polyelectrolyte. Carbohydr Res 1997;302(1-2):7-12 (Pubitemid 27343471)
22. Yan C, Chen D, Gu J, et al. Preparation of N-Succinyl-chitosan and their physical-chemical properties as a novel excipient. Zakugaki Zasshi 2006;126(9):789-93; The Pharmaceutical Society of Japan (Pubitemid 44358777)
23. Mourya VK, Inamdar NN, Tiwari A. Carboxymethyl chitosan and its applications. Adv Mat Lett 2010;1(1):11-33
24. Park IK, Ihm JE, Park YH, et al. Galactosylated chitosan (GC)-graft-poly (vinyl pyrrolidone) (PVP) as hepatocyte-targeting DNA carrier. Preparation and physicochemical characterization of GC-graft-PVP/DNA complex (1). J Control Release 2003;86(2-3):349-59 (Pubitemid 36084278)
25. Holappa J, Nevalainen T, Safin R, et al. Novel water-soluble quaternary piperazine derivatives of chitosan: synthesis and characterization. Macromol Biosci 2006;6(2):139-44
26. Verheul RJ, Amidi M, van der Wal S, et al. Synthesis, characterization and in vitro biological properties of O-methyl free N, N, N-trimethylated chitosan. Biomaterials 2008;29(27):3642-9
27. Thanou M, Florea BI, Langemeyer MW, et al. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res 2000;17(1):27-31 (Pubitemid 30121095)
28. Hamman JH, Stander M, Kotze AF. Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 2002;232(1-2):235-42 (Pubitemid 34076769)
29. Senel S, Kas HS, Squier CA. Application of chitosan in dental drug delivery and therapy. In: Muzzarelli RAA, editor. Chitosan per os: from dietary supplement to drug carrier. Arec. Grottammare; Italy: 2000. p. 241-56
30. Senel S, McClure SJ. Potential applications of chitosan in veterinary medicine. Adv Drug Deliv Rev 2004;56(10):1467-80 (Pubitemid 38748827)
31. Snyman D, Hamman JH, Kotze AF. Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev Ind Pharm 2003;29(1):61-9 (Pubitemid 36205882)
32. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217(1-2):183-91 (Pubitemid 32268644)
33. Soane RJ, Frier M, Perkins AC, et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999;178:55-65 (Pubitemid 29074407)
34. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11(9):1358-61 (Pubitemid 24287420)
35. Dodane V, Amin Khan M, Merwin Jr. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21-32 (Pubitemid 29229791)
36. Wu Y, Wei W, Zhou M, et al. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials 2012;33(7):2351-60
37. Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51(1-3):81-96 (Pubitemid 32763074)
38. Ghendon Y, Markushin S, Vasiliev Y, et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol 2009;81(3):494-506
39. Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009;8(7):937-53
40. Senel S. Chitosan-based particulate systems for non-invasive vaccine delivery. Adv Polym Sci 2011;243:111-38
41. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38(10):2636-49
42. Jabbal-Gill I, Fisher AN, Rappuoli R, et al. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998;16(20):2039-46 (Pubitemid 28473954)
43. McNeela EA, O'Connor D, Jabbal-Gill I, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2001;19(9-10):1188-98 (Pubitemid 32008285)
44. Bacon A, Makin J, Sizer PJ, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000;68:5764-70
45. Hagenaars N, Verheul RJ, Mooren I, et al. Relationship between structure and adjuvanticity of N, N, N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 2009;140(2):126-33
46. Svindland SC, Jul-Larsen A, Pathirana R, et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses 2012;6(2):90-100
47. Rauw F, Gardin Y, Palya V, et al. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunopathol 2010;134(3-4):249-58
48. Rauw F, Gardin Y, Palya V, et al. Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old. Vaccine 2010;28(3):823-33
49. Xie Y, Zhou NJ, Gong YF, et al. Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 2007;13(10):1547-53 (Pubitemid 46672663)
50. McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22(8):909-14 (Pubitemid 38221084)
51. Read RC, Naylor SC, Potter CW, et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005;23:4367-74 (Pubitemid 40991223)
52. European Commission FP7 programme. Available from: http://cordis.europa. eu
53. Hagenaars N, Mania M, de Jong P, et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 2010;144(1):17-24
54. Wimer-Mackin S, Hinchcliffe M, Petrie CR, et al. An intranasal vaccine targeting both the bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006;24(18):3953-63
55. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010;202(11):1649-58.Erratum in: J Infect Dis. 2011;203(7):1036
56. Amidi M, Pellikaan HC, Hirschberg H, et al. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine 2007;25(37-38):6818-29 (Pubitemid 47332722)
57. Mills KH, Cosgrove C, McNeela EA, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. Infect Immun 2003;71:726-32 (Pubitemid 36150765)
58. Alleman E, Grrny R, Doelker E. Drug-laoded nanoparticles-preparation methods and drug targeting issues. Eur J Pharm Sci 1993;4:23-31
59. Tiyaboonchai W, Woiszwillo J, Middaugh CR. Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur J Pharm Sci 2003;19(4):191-202 (Pubitemid 36918411)
60. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 2010;58(11):1423-30
61. Pan Y, Li YJ, Zhao HY, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002;249(1-2):139-47 (Pubitemid 35333440)
62. Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007;329(1-2):142-9 (Pubitemid 44937518)
63. Erbacher P, Zou S, Bettinger T, et al. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 1998;15(9):1332-9 (Pubitemid 28427918)
64. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14(10):1431-6 (Pubitemid 27481075)
65. Tang ZX, Qian JQ, Shi LE. Preparation of chitosan nanoparticles as carrier for immobilized enzyme. Appl Biochem Biotechnol 2007;136(1):77-96
66. Jiang HL, Kang ML, Quan JS, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 2008;29(12):1931-9
67. O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods 2006;40(1):10-19; Review (Pubitemid 44415494)
68. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004;21(4):671-4 (Pubitemid 38457290)
69. Gunbeyaz M, Faraji A, Ozkul A, et al. Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci 2010;41(3-4):531-45
70. Slutter B, Plapied L, Fievez V, et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 2009;138(2):113-21
71. Kotze AF, Thanou MM, Luessen HL, et al. Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur J Pharm Biopharm 1999;47(3):269-74 (Pubitemid 29257886)
72. Sayin B, Somavarapu S, Li XW, et al. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 2009;38(4):362-9
73. Slutter B, Bal S, Keijzer C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010;28(38):6282-91
74. Keijzer C, van der Zee R, van Eden W, et al. PLGA, PLGA-TMC and TMC-TPP nanaoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 2011;46:11
75. Vila A, Sanchez A, Janes K, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004;57(1):123-31 (Pubitemid 38058811)
76. Borges O, Cordeiro-da-Silva A, Romeijn SG, et al. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release 2006;114(3):348-58 (Pubitemid 44310817)
77. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1(1):1-9; Review
78. Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007;33(10):1112-24 (Pubitemid 350034832)
79. Pokharkar V, Bhumkar D, Suresh K, et al. Gold nanoparticles as a potential carrier for transmucosal vaccine delivery. J Biomed Nanotechnol 2011;7(1):57-9
80. Chen F, Zhang ZR, Yuan F, et al. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm 2008;349(1-2):226-33 (Pubitemid 350299699)
81. Borges O, Tavares J, de Sousa A, et al. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 2007;32(4-5):278-90 (Pubitemid 350051890)
82. Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm 2005;297(1-2):223-34 (Pubitemid 40720281)
83. Debache K, Kropf C, Schutz CA, et al. Vaccination of mice with chitosan nanogel-associated recombinant NcPDI against challenge infection with neospora caninum tachyzoites. Parasite Immunol 2011;33(2):81-94
84. Gupta RK, Relyveld EH, Lindblad EB, et al. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993;11(3):293-306
85. Klas SD, Petrie CR, Warwood SJ, et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 2008;26(43):5494-502
86. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011;365(23):2178-87
87. Borges O, Cordeiro-da-Silva A, Tavares J, et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008;69(2):405-16
88. Yue Y, Xu W, Hu L, et al. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 2009;386(2):438-47
89. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 2004;82(6):628-37 (Pubitemid 39567324)
90. Iqbal M, Lin W, Jabbal-Gill I, et al. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003;21(13-14):1478-85 (Pubitemid 36263189)
91. Wang X, Zhang X, Kang Y, et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 2008;26(40):5135-44
92. Khatri K, Goyal AK, Gupta PN, et al. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008;26(18):2225-33
93. Xu J, Dai W, Wang Z, et al. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by streptococcus pneumoniae. Clin. Vaccine Immunol 2011;18(1):75-81
94. Yu M, Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010;10(8):1181-95
95. Senel S. Applications of chitosan and its derivatives in veterinary medicine. In: Se-Kwon K, editor. Chitin, chitosan, oligosaccharides and their derivatives biological activities and applications. CRC Press; South Korea: 2010. p. 461-78
96. Kang ML, Kang SG, Jiang HL, et al. Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. J Microbiol Biotechnol 2008;18(6):1179-85
97. Cokcaliskan C, Gursoy RN, Gunbeyaz M. Chitosan for mucosal immunization against foot and mouth disease. Presented at: 35th Annual Meeting and Exposition of the Controlled Release Society; 12-16 July 2008; New York, USA
98. MUCOVAC2: Phase I clinical trial to assess the safety and immunogenicity of three HIV CN54gp140 immunisations administered through the intramuscular, intranasal and intravaginal routes in healthy female volunteers. Available from: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11679 http://www.iavireport.org/archives/2012/pages/IAVI-Report-16(1)-Vaccine-Briefs. aspx [Both accessed 27 March 2012]
99. Pawar D, Goyal AK, Mangal S, et al. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010;12(2):130-7
100. Gupta NK, Tomar P, Sharma V, Dixit VK. Development and characterization of chitosan coated poly-("-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 2011;29(48):9026-37
101. Slutter B, Jiskoot W. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release 2010;148(1):117-21
102. Verheul RJ, Slutter B, Bal SM, et al. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for intranasal and intradermal vaccination. J Control Release 2011;156(1):46-52
103. Bal SM, Slutter B, Verheul R, et al. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant-and site-dependent immunogenicity in mice. Eur J Pharm Sci 2012;45(4):475-81
104. Sayin B, Somavarapu S, Li XW, et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 2008;363(1-2):139-48